APOGEN will promote, on October 7, 2020, the e-conference “Value in Health – the Commitment of Generic and Biosimilar Medicines”. The session will be transmitted via streaming, between 09:15 and 12:30. Registration is free.
[dropcap]T[/dropcap]opics such as Health Value, Cost and Financing in Oncological Disease will be addressed, as well as the contribution of generic and biosimilar medicines to generate health value by guaranteeing health outcomes that are important to patients, but in a more accessible way.
The initiative will bring together health professionals, academics, hospital administrators, health economists and patient associations, with the aim of jointly compiling Recommendations for the Portuguese Presidency of the Council of the European Union 2021.
Due to the pandemic caused by COVID-19, many patients with other pathologies have faced difficulties in accessing appointments, exams and surgeries in good time; more than 15,000 cancers will have been left undiagnosed; more than 4 490 deaths remained unexplained. Consequently, the health system will be confronted with more serious cases – in all pathologies – that will require greater investment in health professionals, services and resources in health technologies.
This will be one of the main themes of the e-conference promoted by APOGEN, which will address the direct contribution of generic and biosimilar medicines in the treatment of the disease, as well as their indirect contribution through efficiency gains.
The savings generated can be reinvested in other health resources that ensure equitable access to preventive measures, health care and health technologies for all citizens.
Increasingly, and particularly in a period of health and economic crisis, these medicines are an important structural instrument of accessibility and financial sustainability for Portuguese families and for the general state budget.
